2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2014 Featured Talks » Malignant Reprogramming and Cancer Stem Cells

Catriona Jamieson, part 1 from MCC Industry Relations on Vimeo.

Catriona Jamieson, part 2 from MCC Industry Relations on Vimeo.

Catriona Jamieson, MD, PhD
Associate Professor of Medicine, Hematology-Oncology
Director, Stem Cell Research Program, Moores Cancer Center

Catriona Jamieson, MD, PhD is Associate Professor of Medicine in the Division of Hematology-Oncology and Director for Stem Cell Research at Moores Cancer Center. Dr. Jamieson specializes in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies.